|
Volumn 99, Issue 2, 2006, Pages 123-124
|
Management of rare diseases
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZIRIDINE;
ORPHAN DRUG;
CANCER RISK;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
DRUG MANUFACTURE;
DRUG SAFETY;
GOVERNMENT REGULATION;
HEALTH SERVICE;
HUMAN;
LAW;
LETTER;
LICENSING;
MEDICAL LITERATURE;
PRIORITY JOURNAL;
PUBLICATION;
RARE DISEASE;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
TAX;
|
EID: 32244446588
PISSN: 14602725
EISSN: 14602393
Source Type: Journal
DOI: 10.1093/qjmed/hcl006 Document Type: Letter |
Times cited : (1)
|
References (6)
|